Business Wire

The Future According to Barilla: New Sustainability Report Issued

Share

Barilla Group has released its latest Sustainability Report, as well as its objectives for 2030, confirming sustainability as a strategic pivot for the future. A commitment that has earned Barilla the recognition, for the second year running, as the leading food company in the world by reputation according to Global RepTrak® 100.

The road will be long and complex as always, but thanks to the commitment and passion of our People we are ready to continue the journey with the same intensity and determination with which we began,” state Guido, Luca and Paolo Barilla.

The vision for a more resilient, efficient and future-oriented agriculture involves over 7,000 farmers and 815,000 tons of raw materials purchased according to the specifications of Barilla’s sustainable farming programmes on durum wheat, common wheat, rye, and basil. The Group also supports farmer education through initiatives like Accademia Basilico, offering specialized training to empower farmers and teach techniques for sustainable basil cultivation.

Looking ahead, Barilla also intends to encourage progressive diffusion of regenerative agriculture, with the aspiration of reaching a supply of 250,000 tons of raw materials from certified regenerative production by 2030.

Barilla already uses 48% of its electricity from renewable sources and in the last five years has installed 4 MW of photovoltaic systems for self-generation at its plants. According to the €168 million Energy & Water Plan, it will manage to install a total of 24 MW by 2030 and targets a 250% increase in recycled and reused water in water-stressed areas.

Its people-first approach remains central: Barilla achieved gender pay parity in 2020 and introduced a policy guaranteeing all parents at least 12 weeks of fully paid leave, regardless of gender or marital status. Currently, 35% of Executives and Managers are women, with a target of 40% by 2030, reinforcing the ambition to build an inclusive and equitable workplace.

With its commitment to people's well-being, the Group continues to improve its products and make them tasty, safe and suitable for a proper, balanced diet. In 2024, 88% of volumes sold contain ≤5 grams of sugar and ≤0.5 grams of salt per serving, while 90% are a source of fiber. Last year, Barilla also donated over 3,700 tons of food and more than €2 million to support communities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250709705517/en/

Contacts

Elena Botrytis: elena.botturi@barilla.com, +31642472860

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development10.7.2025 03:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies. Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen’s RenMice® fully human antibody platform. Building on this established collaboration, the new agreement expands the partnership into antibody license, further strengthening the strategic relationship between the two companies. Dr. Yuelei Shen, President and CEO of Biocytogen, said, “BeOne Medicines is a global leader in drug development, and we are thrilled to enter into this strategic collaboration. The antibodies licensed under this agreement were discovered using our proprietary RenMice® fully human antibody platform, highlighting o

IFF to Release Second Quarter 2025 Results on Aug. 5, 20259.7.2025 23:15:00 EEST | Press release

IFF (NYSE:IFF) today announced that it will release its second quarter 2025 earnings results following the market close on Tuesday, Aug. 5, 2025. The management team will host a live webcast on Wednesday, Aug. 6, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20250709408179/en/

Celebrate Excellence: 2026 SPIE Prism Awards Open for Outstanding Photonics Products9.7.2025 19:07:00 EEST | Press release

Applications are now open for the 2026 SPIE Prism Awards. The awards, presented by SPIE, the international society for optics and photonics, recognize the most innovative products on the market, across the growing range of optics and photonics applications. The annual industry event will celebrate its 18th anniversary on 21 January, during a gala evening at SPIE Photonics West. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709679785/en/ SPIE is now welcoming submissions for its 2026 Prism Awards. In 2026, award category areas will include biophotonics instruments, cameras and imaging systems, lasers, optical materials and components, quantum tech, sensors, test and measurement, and XR tech. And now in its third year, SPIE will showcase the SPIE Catalyst Award, recognizing for-profit companies with programs that expand workplace access and opportunity, strengthen community engagement and education, and drive environmental

SK Capital Has Entered Into Exclusive Negotiations to Acquire LISI Group’s Medical Division9.7.2025 18:45:00 EEST | Press release

SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, today announced that its affiliate has entered into exclusive negotiations with LISI Group (Euronext: FII) to acquire LISI Group’s Medical division (“Lisi Medical” or the “Company”). The transaction remains subject to the approval of the competent antitrust authorities, foreign direct investment control authorities and to the information and consultation processes of the relevant employee representative bodies in accordance with applicable laws. As such, the transaction is expected to close in the second half of 2025. Lisi Medical is a leading MedTech CDMO focused on the production of high-precision metal components and assemblies serving global medical device original equipment manufacturers (“OEMs”). The Company’s products include instruments utilized in minimally invasive and robotic-assisted surgery as well as orthopedic implan

LambdaTest Enables Playwright Testing on iOS Real Devices to Enhance Mobile Test Accuracy9.7.2025 18:00:00 EEST | Press release

LambdaTest, a GenAI-powered quality engineering platform, has announced support for Playwright testing on real iOS devices, enabling mobile web teams to run automated tests on actual iPhones and iPads using Safari. This update helps QA and engineering teams validate user experiences with far greater accuracy than simulators or emulators can offer. Testing mobile web apps on virtual environments often leads to discrepancies in real-world behavior such as missed touch interactions, inconsistent browser rendering, and undetected performance bottlenecks. LambdaTest now eliminates that uncertainty by allowing developers to execute Playwright tests on physical iOS devices. While Playwright itself does not natively support real iOS hardware, LambdaTest’s integration bridges that gap, providing seamless access to Apple’s Safari browser on real devices. Users can integrate directly with their CI/CD pipelines, run parallel tests across devices, and access rich debugging artefacts like network lo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye